London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
?
A link to the full RNS as a lot of people don't seem to have seen it? http://www.tyratech.com/wp-content/uploads/2017/12/RNS_120417.pdf
According to Interactive Investor today the Human Lice product part of the company has been sold to Alliance Pharma for an initial payment of $13 million. Hence the rise in SP.
It is not a change sir. there are two share classes with differing tickers!!
As e planned numerous times before Tyr and TYRU are different classes of the shares and priced differently
So now it's tyr and not tyru
49.69k ....the big sell
The only reference to any reason for that trial to be terminated was that it was "very expensive"to conduct.. Subsequent to the trial ending,TYRU included this comment in their June 2012 interim statement :- "Functional Food The Company continues to work closely with its partner Kraft Foods on a joint effort designed to accelerate monetization of the functional food project. Additionally, the Company has demonstrated that its formulations control parasites that are resistant to two commonly used anthelmintic (anti-parasitic) products, benzamidizole and levamisole. These findings also open up a new opportunity to divest a potentially important use to pharmaceutical companies to develop both OTC and prescription pharmaceuticals for human use, in addition to important implications in Animal Health." We will just have to see how things pan out regarding the out licensing,as referred to on the TYRU thread. Have a good weekend !
An Evaluation of a Novel Food Product in Adults Residing in an Area Endemic for Helminths - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov › NCT01271049 TyraTech Technology. Information provided by (Responsible Party):. Mondelēz International, Inc. ClinicalTrials. gov Identifier: NCT01271049. First received: January 3, 2011. Last updated: December 11, 2012. Mondelez International were formerly known as Kraft.
Thanks ivyspivey. Global corporate Mondelez International (Market Cap US$ 66 BILLION with over 100,000 employees)and micro cap Tyratech jointly develop and design a safe, natural and non-toxic solution for intestinal parasites that is deployable as a daily maintenance solution through several platforms and has potential applications for both human and animal health applications.. "High value technology solution" "Proprietary breakthrough technology" You couldn't make this up !
Nice find About Mondelēz International Mondelēz International, Inc. (NASDAQ:MDLZ) is building the best snacking company in the world, with 2016 net revenues of approximately $26 billion. Creating more moments of joy in approximately 165 countries, Mondelēz International is a world leader in biscuits, chocolate, gum, candy and powdered beverages, featuring global Power Brands such as Oreo and belVita biscuits; Cadbury Dairy Milk and Milka chocolate; and Trident gum. Mondelēz International is a proud member of the Standard and Poor's 500, NASDAQ 100 and Dow Jones Sustainability Index. Visit www.mondelezinternational.com or follow the company on Twitter at www.twitter.com/MDLZ.
This is interesting for TYRU investors. Global corporate Mondelez and tiny Tyratech seek to license TYRU technology. https://ninesights.ninesigma.com/web/mondelez-international-gallery/needs-listing/-/needs-portlet/viewNeed?_NeedsPortlet_WAR_NeedPortletsportlet_needId=644 The closing date is later this month. VERY INTERESTING imo.
Any genuine investor tyr tyru pls rt @jp_786 and for those that know vamousse is great and so are the other products but vamousse need to take off like a storm so product placement is on the cards those shopping in supermarkets do your self a favour when u see vamousse pick it up put the bottle on the best selling shampoos for more advertisement then repeat the exercise everytime you pop in slowly but shortly this is a good co that needs the rest of the products out it can only do it if the products on the shelf are flying ty
Large 0 £12k I wonder why
Good to see it on sale at Boots, Marylebone High St albeit at a discount!
We should get some news on one or more of the following soon : -Progress update on new PureScience brand. The animal health market is huge $12BN mkt according to TYRU website. I know they were only set up this year but I can't find anything about them on Google... -I reckon there is a chance that AMVAC could bid for the company or at least increase their holding; currently 15.15%. They also have a history of buying smaller smaller companies / subsidsiaries too see p.4 of presentation here: http://www.americanvanguard.com/Por...ns/AVD Investor Presentation - March 2016.pdf -Envance Technologies (JV with AMVAC): http://envancetech.com/markets/ -New II TR-1's and or increase in holdings. -Increase in sales of Guardian mosquito repellant due awful Zika virus. Welcome other's thoughts on the above...
A few good buys recently
http://tinyurl.com/po3nmo4 Bruno Jactel, chief executive of life sciences technology group TyraTech Inc (LON:TYR), says the firm’s Vamousse treatment, as of December 2015, is now “the fastest growing head lice product in the US, and we are the number one non-pesticide product”. He speaks to Proactive after Tyratech posted a 154% increase in gross product revenue to $7.1mln in the year to the end of December. Jactel adds that the company is now focused on “growth and the pathway to profitability,” with three key areas for long-term growth – expanding its distribution network in existing markets, penetrating other markets including animal health, and moving into new geographies.
It is me who apologises. Misled by the 4/12 and looking for the rise
Sorry did not realise it was 3 years old so forget everything I said
Hi Bruce The few of us are on the TYRU site but all the RNSs come put on TYR- wish they would only list on one platform
No one has remarked on the RNS 26 November that Qctopus have taken no less than 19% of the shares. Hugely interesting. Where are you all?
I don't have any recent experience of this but some of the treaments we tried when my kids came home from school with headlice, were such powerful chemicals we had to stop using them as they made the kids cry. That's 10year + info, for what it's worth.
http://tinyurl.com/pgtar2s Bruno Jactel, chief executive of TyraTech (LON:TYR), gives his growth outlook for the company’s head lice treatment – Vamousse - and comments on the firm’s plans to launch alternatives to pesticides in the animal health market. Today the firm said that despite the two major US pharmacy chains placing its lice treatment in stores later than expected, product sales increased by a factor of more than three times compared to last year’s first half. Its Vamousse shampoo, which drove the increase, was the fastest growing branded head lice product in the US. Speaking to Proactive, Jactel adds that the group's progress in the animal health markets is ongoing, with products previously licensed to Novartis expected to generate sales next year.